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Abstract 
Background: Hyperglycemia is associated with increased morbidity and mortality in patients with an acute myocar-
dial infarction (AMI). We evaluated whether complications after AMI are associated with absolute or relative glycemia.
Methods: A total of 192 patients with AMI were randomized to intensive or conventional insulin therapy. Absolute 
glycemia was defined as mean blood glucose level (BGL) during the first 24 h following randomization. Relative 
glycemia was defined by the stress hyperglycaemia ratio (SHR), calculated as mean BGL divided by average glucose 
concentration over the prior 3 months estimated from glycosylated haemoglobin. The primary endpoint was a “com-
plicated AMI”, defined as an AMI complicated by death, congestive cardiac failure, arrhythmia, cardiac arrest, reinfarc-
tion, cardiogenic shock, inotrope use or emergency revascularization.
Results: There was not a significant association between mean BGL and complicated AMI (odds ratio (OR) 1.05 per 
mmol/L glucose increment, 95% confidence intervals (CI) 0.93–1.19). In contrast, SHR was positively associated with a 
complicated myocardial infarction (OR 1.22 per 0.1 SHR increment, 95% CI 1.06–1.42), and individual complications of 
death (OR 1.55, 95% CI 1.14–2.11), congestive cardiac failure (OR 1.27, 95% CI 1.05–1.54), arrhythmia (OR 1.31, 95% CI 
1.12–1.54) and cardiogenic shock (OR 1.42, 95% CI 1.03–1.97). The relationship between SHR and a complicated AMI 
was independent of diabetic status, intensive insulin therapy, sex and hypoglycemia.
Conclusions: Relative, but not absolute, glycemia during insulin treatment is independently associated with com-
plications after an AMI. Future studies should investigate whether basing therapeutic glycaemic targets on relative 
glycemia improves patient outcomes.
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Background
Hyperglycemia is associated with increased morbid-
ity and mortality in hospitalized patients with a variety 
of medical conditions [1–3]. However, while the asso-
ciation between glucose concentration in hospital and 
mortality is strong in patients without known diabetes, 
paradoxically glucose concentration is not as strongly 
associated with mortality in patients with diabetes [2–6]. 
This suggests that background glycemia influences the 
relationship between glucose and mortality in patients 
admitted to hospital.
An elevated blood glucose in a hospitalized patient 
can occur because a patient has poor chronic glycemic 
control or if there is an acute increase in glucose, often 
termed stress hyperglycemia [7]. Stress hyperglycemia is 
the relative increase in glucose in response to an inter-
current illness. Our group has recently proposed a novel 
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metric for relative glycemia termed the stress hypergly-
cemia ratio (SHR), whereby admission glucose concen-
tration is corrected for background glycemia estimated 
from glycated hemoglobin  (HbA1c) [8]. We reported that 
SHR was associated with critical illness in hospitalized 
patients, independent of absolute glycemia. Moreover, 
the association between relative glycemia and critical 
illness was present in patients with and without back-
ground hyperglycemia. Since this publication, several 
other studies have reported that relative glycemia at hos-
pital admission predicts outcomes for patients admitted 
to hospital with a stroke [9], acute illness [10], acutely ill 
requiring intensive care unit (ICU) admission [11] and 
after percutaneous coronary intervention [12]. These 
studies demonstrate that quantifying relative hypergly-
cemia at admission to hospital provides important prog-
nostic information in patients with and without diabetes.
Calculation of relative hyperglycemia could also poten-
tially provide a basis for individualized glycemic targets 
in patients treated with insulin in hospital. If relative 
hyperglycemia during glucose-lowering treatment was 
associated with adverse patient outcomes, it would sup-
port this hypothesis. However, in our previous study 
blood glucose levels (BGLs) were not systematically 
recorded in all patients throughout the hospital admis-
sion and this analysis could not be undertaken [8].
The hyperglycemia: intensive insulin infusion in infarc-
tion (HI-5) study was a prospective randomized-con-
trolled trial investigating the effect of intensive insulin 
therapy on mortality in patients with an acute myocardial 
infarction [13]. In the primary analysis, there was no sig-
nificant difference in mortality in patients randomized to 
intensive insulin and conventional care. However, as finger 
prick BGLs were systematically recorded in both groups, 
the study cohort provides an opportunity to investigate 
the association between relative hyperglycemia during 
glucose-lowering treatment and adverse patient outcomes.
We hypothesized that, in the HI-5 study cohort, relative 
hyperglycemia during the first 24 h following AMI would 
be more strongly associated with an adverse outcomes for 
patients than absolute glycemia. If true, this would provide 
supportive evidence for a change in treatment paradigm 
whereby glucose-lowering treatment in patients following 
an AMI is targeted at relative, rather than absolute, hyper-
glycemia. Therefore, the aim of this study was to assess the 
relationship between relative glycemia and complications 
following a myocardial infarction and whether this relation-
ship was affected by other potential confounding factors.
Methods
Study design
This is a secondary analysis of a prospective randomized-
controlled trial that has previously been reported [13]. 
In brief, consecutive consenting patients presenting 
with an AMI at six hospitals in New South Wales, Aus-
tralia with either known diabetes or without diabetes and 
BGL > 7.8 mmol/L were randomized to receive insulin/
dextrose infusion therapy for at least 24 h to maintain fin-
ger prick BGL between 4 and 10 mmol/L or conventional 
therapy comprising their usual glucose-lowering therapy 
except metformin and supplemental subcutaneous short-
acting insulin if finger prick BGL was ≥ 16 mmol/L. BGL 
were recorded at 8 pre-defined timepoints in all patients 
(0700, 0900,1200, 1400, 1700, 1900, 2200 and 0300 in all 
patients). Additional BGLs were performed on an hourly 
basis in patients on intensive insulin therapy. The study 
was approved by local ethics committees of Westmead 
Hospital, Nepean Hospital, Blacktown Hospital, Mt. 
Druitt Hospital and John Hunter Hospital. All subjects 
participating in the study provided written informed 
consent.
Subjects
This analysis included all participants in the HI-5 study 
in whom  HbA1c was measured at admission to hospital. 
Patients were treated with angioplasty, thrombolysis or 
anti-coagulation at the discretion of the admitting doc-
tors. All patients received beta blocker therapy unless 
specifically contraindicated [13]. Demographic data, lab-
oratory data, and in-hospital mortality and complications 
that were recorded at the time of the original study were 
used in the analysis. A Charlson Comorbidity Index was 
calculated from the co-morbidities recorded during the 
original data collection [14].
Calculation of stress hyperglycemia ratio
Finger prick point of care capillary BGLs were measured 
at predefined time points during the first 24 h as previ-
ously described [13], and the readings were averaged to 
calculate mean BGL during glucose-lowering treatment 
for each subject. Estimated average glucose over the prior 
3  months was calculated using the equation “estimated 
average glucose  =  (1.59  ×  HbA1c)  −  2.59” derived by 
Nathan et al. [15] Relative hyperglycemia during glucose-
lowering treatment (SHR) was then calculated using the 
formula mean BGL divided by estimated average glucose.
Statistical methods
Before undertaking this secondary analysis we pre-spec-
ified a composite primary endpoint of a “complicated 
AMI,” defined as AMI complicated by death during the 
hospital admission, congestive cardiac failure, arrhyth-
mia, cardiac arrest, reinfarction, cardiogenic shock, 
inotrope use or the need for rescue percutaneous trans-
luminal coronary angioplasty (PTCA) or emergency 
coronary arterial bypass graft (CABG). These events 
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were defined as per the original HI-5 study [13]. Rein-
farction was defined as a new AMI that occurred at least 
72 h following the index AMI. A patient was considered 
in congestive cardiac failure if there was documented 
dyspnea in the notes and the chest X-ray report con-
firmed pulmonary edema or interstitial edema. Cardio-
genic shock referred to a state where the patient was in 
cardiac failure with a concomitant systolic blood pres-
sure of less than 80  mmHg. The primary variables of 
interest were absolute hyperglycemia, defined as mean 
BGL during glucose-lowering treatment and relative 
hyperglycemia, defined as SHR during glucose-lowering 
treatment.
Characteristics of patients with and without a com-
plicated AMI are reported as mean  ±  standard devia-
tion if normally distributed and median (interquartile 
range) if the distribution was not normal. These variables 
were compared using unpaired t tests, Mann–Whitney 
U tests or Chi squared tests as appropriate. Univariable 
binomial logistic regression analyses were undertaken to 
calculate the odds ratio of a complicated AMI for each 
BGL and SHR increment. Odds ratios for the individual 
components of the composite primary endpoint for each 
BGL and SHR increment were also calculated. We then 
included treatment group and known diabetes and inter-
action terms for these variables as co-variates in analy-
ses to assess whether they moderated the relationship 
between SHR and a complicated AMI. Finally, univari-
able binomial logistic regression analyses were under-
taken to examine whether other variables of interest such 
as sex, age, Charlson Comorbidity Index, hypoglyce-
mia, treatment type and peak creatinine phosphokinase 
were associated with a complicated AMI. If a variable 
was not normally distributed, it was log-transformed to 
achieve a normal distribution before inclusion in regres-
sion analyses. Variables that were significantly associated 
with a complicated AMI in a univariable analysis were 
then included in a multiple binomial logistic regression 
analysis.
Statistical analysis was undertaken using SPSS version 
23 for Windows (IBM, New York, USA). A two-tailed p 
value of < 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 192 subjects were included in the final analysis; 
48 patients out of the 240 patients included in the origi-
nal study cohort were excluded as there were no recorded 
 HbA1c. In this cohort, 82 patients were defined as hav-
ing a complicated AMI: 6 patients died, 22 developed 
congestive cardiac failure, 48 had an arrhythmia, 21 had 
a cardiac arrest, 3 had a re-infarction, 5 developed car-
diogenic shock, 10 were treated with inotropic support, 
26 required a rescue PTCA and 7 an emergency CABG. 
A number of subjects had more than one complication. 
Although subjects with a complicated AMI were more 
likely to be female, there were no significant differences 
in age, Charlson Comorbidity Index, intensive insulin 
therapy, known diabetes, other cardiovascular risk fac-
tors, cardiovascular medications, serum cholesterol, 
peak creatinine phosphokinase and use of anticoagulant, 
thrombolytic and angioplasty treatment and ST eleva-
tion on ECG between patients with a complicated and 
uncomplicated AMI (Table 1).
Associations between absolute and relative glycemia 
during glucose‑lowering treatment and a complicated 
acute myocardial infarction
There was not a significant association between mean 
BGL and the incidence of complicated AMI (odds ratio 
(OR) 1.05 per mmol/L glucose increment, 95% confi-
dence intervals (CI) 0.93–1.19, p = 0.437) (Fig. 1a). Fur-
thermore, no individual component of the composite 
“complicated AMI” endpoint was significantly associated 
with mean BGL (Fig. 1a). In contrast, SHR was associated 
with a complicated AMI (OR 1.22 per 0.1 SHR incre-
ment, 95% CI 1.06–1.42, p  =  0.006) (Fig.  1b). Moreo-
ver, SHR was positively associated with death (OR 1.55, 
95% CI 1.14–2.11, p = 0.005), congestive cardiac failure 
(OR 1.27, 95% CI 1.05–1.54, p = 0.014), arrhythmia (OR 
1.31, 95% CI 1.12–1.54, p = 0.001) and cardiogenic shock 
(OR 1.42, 95% CI 1.03–1.97, p  =  0.033). SHR was not 
significantly associated with cardiac arrest, reinfarction, 
inotrope use, rescue angioplasty or emergency CABG 
(Fig. 1b).
Effect of diabetes and intensive insulin therapy 
on association between relative glycemia and a 
complicated acute myocardial infarction
Figure 2a shows that the relationship between SHR and 
a complicated AMI was similar in patients with and 
without diabetes. The association between SHR and 
a complicated AMI was independent of diabetes sta-
tus (OR 1.38 per 0.1 SHR increment, 95% CI 1.08–1.75 
p = 0.009), which was not independently associated with 
a complicated AMI (p = 0.204). Furthermore there was 
not a significant interaction between SHR and diabetes 
status (p  =  0.216), demonstrating that diabetes status 
did not significantly modulate the relationship between 
SHR and a complicated AMI. Figure  2b shows that the 
relationship between SHR during insulin treatment and 
a complicated AMI was not different in patients rand-
omized to intensive insulin and conventional therapy. 
The association between SHR and a complicated AMI 
was independent of intensive insulin therapy (odds 
ratio = 1.37 per 0.1 SHR increment, 95% CI 1.09–1.72, 
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p = 0.006), which was not associated with a complicated 
AMI (p =  0.173). Moreover there was not a significant 
interaction between SHR and intensive insulin treatment 
(p  =  0.206), demonstrating that treatment group not 
significantly modulate the relationship between SHR and 
a complicated AMI.
Effect of other variables on a complicated acute myocardial 
infarction
In univariate analyses, female sex (p = 0.015) and hypo-
glycemia (p = 0.015) were significantly associated with a 
greater risk of a complicated AMI (Table 2). Age, Charl-
son Comorbidity Index, treatment of the AMI, peak cre-
atinine phosphokinase and ST elevation on ECG were 
not significantly associated with a complicated AMI. In 
a multiple regression analysis the relationship between 
SHR and a complicated AMI was independent of sex and 
hypoglycemia (Table  2). Female sex and hypoglycemia 
Table 1 Characteristics of patients with and without a 
complicated myocardial infarction
ACE angiotensin converting enzyme, AMI acute myocardial infarction, N number 
of patients with endpoint, CCB calcium channel blocker, LMWH low molecular 
weight heparin, PTCA percutaneous transluminal coronary angioplasty, Peak 
CPK peak creatinine phosphokinase, STEMI ST elevation on ECG or presence of 
Q-waves
Values represent mean (standard deviation) unless otherwise stated; a Median 
(interquartile range); b There were 6 patients missing STEMI status, 2 with 
uncomplicated AMI and 4 with complicated AMI




Age (years) 63 (10) 61 (12) 0.108
Female [N, (%)] 24 (29) 16 (15) 0.017
Charlson Comorbid-
ity  Indexa
0.5 (0.0–1.0) 0.0 (0.0–1.0) 0.843
Intensive insulin 
[N, (%)]
44 (54) 58 (53) 0.898
Diabetes [N, (%)] 38 (46) 53 (48) 0.801
Diagnoses prior to admission
 Hypertension [N, 
(%)]
50 (61) 57 (52) 0.287
 Hyperlipidemia 
(N, (%))
44 (54) 67 (61) 0.388
 Smoker [N, (%)] 26 (32) 35 (32) 0.372
 Previous AMI [N, 
(%)]
20 (24) 21 (19) 0.445
Medications at admission
 ACE inhibitor [N, 
(%)]
16 (20) 23 (21) 0.845
 Aspirin [N, (%)] 19 (23) 28 (25) 0.752
 Beta-blocker [N, 
(%)]
17 (21) 13 (12) 0.098
 CCB [N, (%)] 9 (11) 13 (12) 0.880
 Fibrate [N, (%)] 1 (< 1) 1 (< 1) 0.826
 Nitrate [N, (%)] 11 (13) 16 (15) 0.850
 Statin [N, (%)] 22 (27) 31 (28) 0.918
Initial treatment 0.583
 LMWH/heparin [N, 
((%)]
22 (27) 39 (35)
 Thrombolysis [N, 
(%)]
33 (40) 20 (18)
 Acute PTCA [N, 
(%)]
24 (29) 49 (45)
 Not documented 3 (4) 2 (2)
Total cholesterol 
(mmol/L)
4.67 (1.31) 4.92 (1.23) 0.197
Peak  CPKa 923 (292–3130) 1115 (517–2844) 0.305
STEMI [N, (%)]b 62 (76%) 84 (76%) 0.780
a
b
Fig. 1 Odds ratios for the risk of complications of an acute myocar-
dial infarction in 192 patients. a Complications per 1 mmol/L glucose 
increment and b 0.1 stress hyperglycemia ratio increment. The size 
of the squares represent the observed frequency of each complica-
tion post myocardial infarction while the whiskers represent the 95% 
confidence intervals. CCF = congestive cardiac failure; PTCA = percu-
taneous transluminal coronary angioplasty; CABG = coronary arterial 
bypass graft
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were also independently associated with a complicated 
myocardial infarction.
Discussion
Our secondary analysis of the HI-5 study observed no 
significant association between absolute glycemia dur-
ing glucose-lowering treatment, defined as the mean 
finger prick BGL during the first 24  h post-AMI, and a 
complicated AMI. In contrast, when mean BGL was cor-
rected for background glycemia to estimate relative gly-
cemia, it was positively associated with a complicated 
AMI. Moreover, the association with relative glycemia 
was independent of diabetes status, treatment group and 
a number of other variables that potentially affect the 
prognosis after an AMI. As relative glycemia during glu-
cose-lowering treatment is more strongly associated with 
patient outcomes than absolute glycemia, we hypoth-
esize that defining individualized therapeutic glucose tar-
gets based on relative, and not absolute, glycemia could 
potentially reduce morbidity and mortality after an AMI.
Absolute hyperglycemia and mortality
A number of studies have reported that glucose concen-
tration on admission to hospital is positively associated 
with mortality in patients with an AMI [1, 3, 16–19]. 
Moreover, the association between mortality and mean 
glucose during hospitalization is even stronger than with 
admission glucose [16, 20–22]. In contrast, in the HI-5 
patient cohort mean glucose concentration during glu-
cose-lowering treatment was not significantly associated 
with a complicated AMI or any individual component of 
this composite endpoint. There are a number of poten-
tial explanations for this negative result. Firstly, approx-
imately half the patients in the HI-5 study had diabetes 
and the association between glucose concentration and 
mortality is attenuated in this group [3, 16, 23]. Secondly, 
the primary endpoint of this analysis is a composite and 
there may be individual components of the endpoint that 
are not related to glucose concentration. Most impor-
tantly, the sample size in this analysis is relatively small 
compared to previous studies.
Relative hyperglycemia and mortality
Measurement of  HbA1c in addition to glucose has revo-
lutionized the management of chronic hyperglycemia, 
where  HbA1c is both a diagnostic test for diabetes and 
the primary measurement used to guide the need for and 
efficacy of glucose-lowering therapy [24]. In addition to 
a clear relationship with microvascular disease, a lower 
HbA1c during long-term follow-up has been associated 
a
b
Fig. 2 Rates of a complicated acute myocardial infarction per stress 
hyperglycemia ratio range in 192 patients. a Patients with (black 
diamond, solid line) and without (white circle, dotted line) Diabetes 
Mellitus; and b patients receiving intensive (black diamond, solid line) 
or conventional (white circle, dotted line) glucose-lowering therapy
Table 2 Univariate and multivariate analyses of associa-
tions between selected variables and a complicated acute 
myocardial infarction
NA not assessed, SHR stress hyperglycemia ratio, Peak CPK peak creatinine 
phosphokinase, STEMI ST elevation on ECG or presence of Q-waves
a Log transformed for statistical analysis
b Treatment groups were heparin or low-molecular weight heparin, 
thrombolysis or percutaneous transluminal coronary angioplasty
c There were 6 missing STEMI status which were excluded in this analysis
Variable Univariate Multivariate
β p value β p value
Sex − 0.888 0.015 − 0.917 0.017
Age 0.021 0.108 NA
SHR 0.202 0.006 0.245 0.002
Charlson  Scorea 1.105 0.740 NA
Hypoglycemia 1.109 0.049 1.218 0.038
Treatmentb − 0.094 0.590 NA
Peak  CPKa − 0.382 0.169 NA
STEMIc 0.102 0.779
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with reduced macrovascular disease [25, 26]. It has also 
been hypothesized that  HbA1c could be used to quantify 
stress or relative hyperglycemia and assist management 
of acute hyperglycemia [27, 28]. However, other studies 
have utilized varying definitions of stress hyperglycemia 
based on absolute glucose concentrations, sometimes 
taking a patients’ diabetic status into account [20, 29, 
30]. While it has been proposed that therapeutic targets 
should differ in patients with and without diabetes, the 
optimum method to quantify relative glycemia remains 
to be determined [28, 31]. SHR is a novel metric to quan-
tify relative glycemia in a single numerical value that is 
cheap to measure and simple to calculate. It directly 
relates a patient’s current glucose control during an 
acute presentation to their background glycemia, provid-
ing an individualized quantification of stress or relative 
hyperglycemia.
In contrast to absolute glycemia, relative glycemia 
during glucose-lowering treatment was positively and 
significantly associated with mortality, heart failure, 
arrhythmia, cardiogenic shock and a composite endpoint 
of a complicated AMI in the HI-5 study. These associa-
tions between relative glycemia and a number of adverse 
patient outcomes are striking, given the fairly small 
sample size in this analysis. Our study extends previous 
observations by demonstrating that relative hypergly-
cemia during glucose-lowering treatment is also associ-
ated with adverse outcomes in patients with and without 
diabetes. This suggests that a management strategy that 
selectively targets glucose-lowering therapy for patients 
with an elevated SHR irrespective of prior diabetes status 
may improve outcomes after an AMI.
Others have reported that relative hyperglycemia at 
admission to hospital has been associated with poor out-
comes in patients with acute illness [10], stroke [9], acute 
myocardial infarction [30, 32] and in cardiogenic shock 
[33]. In addition to SHR two other measures of relative 
glycemia have been proposed. The “glycemic gap” is the 
difference between the admission glucose and the esti-
mated average glucose i.e. it is the absolute rather than 
the relative difference in glucose concentration [11, 32, 
34]. Another proposal was for a “glucose concentra-
tion-to-HbA1c ratio”, in which the admission glucose is 
divided by the HbA1c [9]. This is theoretically similar to 
SHR. Whether one measure has advantages over the oth-
ers has yet to be fully determined, although they are likely 
perform similarly [9].
Effects of diabetes status and insulin use
During long-term follow-up of patients with AMI diabe-
tes is associated with increased mortality [35, 36]. How-
ever, during a hospital admission the association between 
absolute glycemia and mortality is stronger in patients 
without, as opposed to with, diabetes [3, 6, 18]. We previ-
ously reported that the relationship between relative gly-
cemia and critical illness was similar in patients with and 
without background hyperglycemia [8]. In this analysis, 
relative glycemia was also associated with a complicated 
AMI independent of diabetes, which was not indepen-
dently associated with a complicated AMI (Fig. 2a). This 
suggests that relative hyperglycemia is clinically impor-
tant regardless of diabetes status.
A potential confounder in this analysis is that half the 
cohort was randomized to intensive insulin therapy, 
which will lower absolute, and consequently relative, 
glycemia. However, the 0.7  mmol/L difference in abso-
lute glucose between the two groups was not statistically 
significant [13]. Furthermore, the positive association 
between relative glycemia and a complicated AMI was 
independent of treatment group. Treatment group itself 
was not independently associated with a complicated 
AMI and there was not a significant interaction between 
treatment group and SHR in regression analysis. This 
suggests that insulin treatment did not confound the 
relationship between relative glycemia and a complicated 
AMI.
Other variables affecting outcomes
The other variables that were independently associated 
with a complicated AMI were female sex and hypogly-
cemia. The association between female sex and a poorer 
outcome after an AMI is consistent with previous studies 
[37, 38]. An association between hypoglycemia after an 
AMI and mortality is well described [16, 19, 39]. How-
ever, previous studies have reported that the association 
is predominantly in patients with spontaneous hypogly-
cemia while not on insulin therapy and at admission to 
hospital [19, 39]. In our study, hypoglycemia during glu-
cose-lowering treatment was independently associated 
with a complicated AMI. This suggests that if a therapeu-
tic approach targeting relative glycemia were to be tri-
alled, it will be important to avoid hypoglycemia.
Some variables that are usually associated with poor 
outcomes after AMI were not statistically significant in 
our analyses. ST elevation was not a predictor of compli-
cated AMI. Our analysis cannot determine the reason for 
this, but we postulate contributory factors include that 
only patients with STEMI were revascularized, the pri-
mary endpoint was composite and that the sample size 
was relatively small. The association between age and 
complicated AMI was positive but did not reach statisti-
cal significance (p = 0.108). Peak CK also did not show an 
association with poorer composite outcomes. Only peak 
CK was measured and recorded, as CKMB and troponin 
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measurements were not routine at the time of the HI-5 
study. Other variables can affect peak CK, such as proce-
dures like PTCA.
Mechanisms linking stress hyperglycemia and patient 
outcomes
An elevation in plasma glucose concentration is poten-
tially an epiphenomenon and not directly contributing to 
cardiovascular events. For example, patients with an AMI 
have elevations of serum cortisol that could mediate both 
an increase in blood glucose and contribute to increased 
cardiovascular risk [40–42]. However, a number of mech-
anisms have been proposed by which stress hyperglyce-
mia could directly increase morbidity and mortality after 
an AMI. These include endothelial apoptosis, endothelial 
dysfunction and oxidative stress [43–46]. Interventional 
studies demonstrating that lowering plasma glucose 
reduces cardiovascular events are needed to confirm that 
stress hyperglycemia per se increases cardiovascular risk.
Studies that have lowered glucose concentration to a 
target absolute glucose range using insulin therapy have 
produced conflicting results [13, 47, 48]. Consequently, 
the importance of this therapeutic approach has not 
been clearly defined, supported only by a low-level of evi-
dence in clinical practice guidelines [20, 49, 50]. As rela-
tive glycemia during glucose-lowering treatment is more 
strongly associated with adverse outcomes, we propose 
that SHR could be used to derive individualized glycemic 
targets for patients with an AMI. If this improved patient 
outcomes it would represent a paradigm shift in the man-
agement of hyperglycemia in hospitalized patients. Treat-
ment of relative hyperglycemia should be the subject of 
future interventional studies.
Strengths and limitation
The strengths of this study include the use of a novel 
metric that quantifies stress hyperglycemia as a con-
tinuous variable, a patient population that reflects usual 
clinical practice, patient data that was systematically and 
prospectively recorded, and defining a pre-specified pri-
mary endpoint before undertaking the analysis. However, 
we acknowledge that the study has limitations. This is a 
retrospective, post hoc analysis, and is thus hypothesis 
generating. The study design cannot show causality, does 
not assess mechanisms by which relative hyperglycemia 
could confer a poorer prognosis and does not distin-
guish whether spontaneous normalization of glucose or 
insulin treatment underlies a relationship between rela-
tive hypoglycemia and a complicated AMI. In particular, 
it cannot distinguish whether relative hyperglycemia is 
simply a marker of the severity or duration of an AMI, 
or directly contributes to poorer outcomes. Moreover, we 
did not assess the effect of other variables in this analy-
sis that potentially affect cardiovascular outcomes, such 
as glycemic variability and postprandial hyperglycemia 
[51, 52]. Another potential limitation is that glucose was 
assessed using point of care BGLs, which may differ from 
gold standard laboratory measurements. However, this 
approach reflects usual clinical practice. Management of 
AMI has also changed since the HI-5 study, notably the 
greater use of PTCA. This could potentially affect results, 
although treatment was not a predictor of outcome in 
this analysis. The mortality rate was fairly low in this 
study and the results may not be able to be extrapolated 
to patient groups with a higher mortality rate. Finally, the 
sample size was relatively small, which may have resulted 
in a type 2 error, especially in subgroup analysis of treat-
ment groups as the numbers of patients in the insulin-
treated group with a high SHR were low. Nevertheless, 
the study was of sufficient size to show a significant inde-
pendent association between relative glycemia and sev-
eral cardiovascular endpoints.
Conclusion
Absolute glucose concentration during glucose-lowering 
treatment following an AMI was not significantly associ-
ated with a complicated AMI. In contrast, SHR was posi-
tively associated with mortality, heart failure, arrhythmia, 
cardiogenic shock and a composite endpoint of a com-
plicated AMI. We conclude that relative glycemia during 
glucose-lowering treatment is more strongly associated 
with adverse outcomes than absolute glycemia in patients 
after an AMI. This research adds to other published 
research by demonstrating the prognostic utility of quan-
tifying relative hyperglycemia during glucose-lowering 
treatment after an AMI, and should provide a basis for 
prospective studies using relative, rather than absolute, 
glycemic thresholds for intervention and therapeutic gly-
cemic targets.
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